Spontaneous Abortion Clinical Trial
— EAGeROfficial title:
The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.
The primary objective of the study is to help elucidate the effects of low-dose aspirin in combination with folic acid on the incidence of live births and spontaneous abortions among a group of women who become pregnant compared to a control group.
Status | Completed |
Enrollment | 1228 |
Est. completion date | July 2012 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Women experiencing one or two pregnancy losses at any point in gestation in the past that were not elective termination(s). At least one of these losses must be well documented by one of the following: - Sonogram demonstrating anembryonic loss, embryonic loss or fetal death. - Histologic confirmation of products of conception that were spontaneously passed per vagina or surgically obtained. - Hospital records of fetus delivery. - Late menses and positive serum hCG or positive urine hCG documented by hospital or clinic records followed by either a negative hospital/clinic pregnancy test or a decline in urinary hCG level over 3 days. - Home pregnancy tests without hCG confirmation from a healthcare provider (either serum or urine) will not be accepted. - No more than 5 pregnancies in total including the pregnancy loss(es).* - Up to two prior pregnancies that did not end in a loss.* *Women may have up to two pregnancies beyond 20 weeks that were not losses, two spontaneous pregnancy losses at any time in the past, and up to one therapeutic or elective termination (two therapeutic or elective terminations if no other pregnancies). Ectopic and molar pregnancies would, for the purpose of enrollment, be considered in the same category as therapeutic termination pregnancies. Women with more than two live births or those with more than two losses, regardless of the week of gestation of the loss, are excluded. - Presence of intact tubes (both), ovaries (both), and uterus. - Between 18 and 40 years of age at time of baseline visit. - Regular menstrual periods between 21 - 42 days in length (within the last 12 months). Regular menstrual periods are defined as no more than an 8-day difference between the woman's shortest and longest cycle. - No more than one missed menses in the past 12 months (other than those missed due to pregnancy or breastfeeding). - Actively trying to conceive with a male partner and not using contraception by the baseline visit. - Not currently pregnant at the baseline or randomization visits. - Ability and willingness to give informed consent. - Willingness to be randomized and to take daily study pills for 6 months to a possible 15 months Exclusions Criteria: - Known allergies to aspirin or non-steroidal anti-inflammatory agents. - Clinical indication for anticoagulant therapy. These include prior or current thrombosis, antiphospholipid syndrome (APS) or known major thrombophilia. - Clinical indication for chronic use of NSAIDs such as rheumatoid arthritis. - Indication for additional folic acid supplementation, such as prior infant with neural tube defect (NTD), seizure disorder. - Medical contraindication to aspirin therapy. These include uncontrolled asthma, nasal polyps, bleeding disorders, or history of gastrointestinal ulcer. - Presence of major medical disorders (regardless of severity). These include diabetes, hypertension, systemic lupus erythematosus (SLE), untreated or active cancer (any cancer in remission or non-melanoma skin cancer is not included in the exclusion criteria), liver disease, renal disease, rheumatoid arthritis, cardiac disease, pulmonary disease other than mild asthma, neurologic disease requiring medical treatment, uncontrolled hypothyroidism, uncontrolled seizure disorder. Untreated vitamin B12 deficiency, severe anemia (Hct < 30%), hemophilia, gout, nasal polyps, among others. - Currently undergoing/planned use of assisted reproductive techniques during trial (IVF; IUI; Clomid). - History of infertility or sub-fertility. This includes any of the following: - No conception after = 1 year of unprotected intercourse and actively trying to conceive. - Any prior medical treatment for infertility. - Prior treatment for known pelvic inflammatory disease. - Known male infertility or sperm abnormality (current partner). - Known tubal occlusion, anovulation, uterine abnormality, or endometriosis stage III or IV. - History of polycystic ovarian syndrome. - Presence of unstable mental disorder. These include bipolar illness, schizophrenia, uncontrolled depression, uncontrolled anxiety disorder. - Known current or recent alcohol abuse or illicit drug use. - Current diagnosis of sexually transmitted infection (STI) (temporary exclusion) |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Women's Health Research Center, Department of Social and Preventive Medicine, University at Buffalo | Buffalo | New York |
United States | University of Colorado, Denver School of Medicine, Department of Obstetrics and Gynecology | Denver | Colorado |
United States | University of Utah Medical Center | Salt Lake City | Utah |
United States | Moses Taylor Hospital | Scranton | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Live Birth | Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff . | after delivery | No |
Secondary | hCG Recognized Pregnancy | within 8-weeks of gestation | Yes | |
Secondary | Clinically Recognized Pregnancy | 8-weeks | Yes | |
Secondary | Early Pregnancy Loss (EPL) | 8 weeks | Yes | |
Secondary | Pregnancy Losses Occurring Less Than 10 Weeks | less than 10-weeks | Yes | |
Secondary | Fetal Pregnancy Loss | until 40 weeks | Yes | |
Secondary | Stillbirth | 40 weeks | Yes | |
Secondary | Ectopic Pregnancy | within 6 weeks | Yes | |
Secondary | Molar Pregnancy | 8 weeks | Yes | |
Secondary | Preeclampsia | until delivery | Yes | |
Secondary | Small for Gestational Age Infant | until delivery | Yes | |
Secondary | Preterm Birth | until delivery | Yes | |
Secondary | Abnormal Fetal Testing | 8 weeks | Yes | |
Secondary | Fetal Intolerance of Labor | until delivery | Yes | |
Secondary | Abruption | until delivery | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02657200 -
Knowledge, Attitude and Practices of Flemish Midwifes Regarding Spontaneous Abortion
|
N/A | |
Recruiting |
NCT03332706 -
the Association Between Blood's and Urinary Heavy Metal Level in Pregnant Women and the Spontaneous Abortion
|
N/A | |
Recruiting |
NCT04003064 -
Heavy Metals' Influence on Early Pregnancy Through Oxidative Stress
|
||
Completed |
NCT01857310 -
Folic Acid and Zinc Supplementation Trial (FAZST)
|
N/A | |
Recruiting |
NCT04456660 -
Comprehensive Assessment of Risks for Miscarriage.
|
||
Completed |
NCT00878098 -
Study of DDT and Loss of Clinically-Recognized Pregnancies in South Africa
|
||
Recruiting |
NCT04705324 -
Dilation and Curettage Versus Operative Hysteroscopy for Missed Abortion
|
N/A | |
Completed |
NCT02012491 -
Comparative Effectiveness of Pregnancy Failure Management Regimens
|
Phase 3 | |
Recruiting |
NCT05492708 -
The Heartland Study
|
||
Completed |
NCT04017754 -
Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)
|
||
Active, not recruiting |
NCT04156126 -
Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer
|
||
Completed |
NCT02725710 -
Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration
|
Phase 2 | |
Recruiting |
NCT04182503 -
Environmental Factors and Embryonic Development Project
|